Key Takeaways:
China's NMPA granted conditional approval to TransThera's tinengotinib (Yochanra) for FGFR2-altered cholangiocarcinoma, the first post-FGFR therapy approved in the country.
The approval, announced by the Nanjing-based company in a filing to the Hong Kong exchange, covers adults with unresectable advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement who received prior systemic therapy and an FGFR inhibitor.
The conditional approval rests on a single-arm Phase II trial of 50 heavily pretreated patients. Blinded independent central review at a median follow-up of 12 months reported an objective response rate of 28 percent, a median duration of response of 8.5 months, and a disease control rate of 82 percent. Median progression-free survival was 6.0 months and median overall survival 20.7 months.
Shares of TransThera (2617.HK) rose as much as 14.92 percent to HKD14.87 and last traded up 14.31 percent at HKD13.18, with turnover of 11.9 million shares worth HKD163 million.
Tinengotinib is a multi-kinase inhibitor targeting FGFR1/2/3, JAK1/2, VEGFR2, and Aurora A/B kinases. Its broader profile is designed to retain activity against acquired resistance mutations such as FGFR2 V564F, which selective FGFR inhibitors often fail to overcome.
The approval fills a distinct niche. Pemigatinib, cleared by the NMPA in 2022, targets FGFR2-altered cholangiocarcinoma in patients who have had prior systemic therapy but not necessarily a prior FGFR inhibitor, placing it earlier in the treatment sequence. HUTCHMED's fanregratinib is also pursuing NMPA approval in FGFR2 fusion-positive disease. Globally, Relay Therapeutics' lirafugratinib, a covalent FGFR2-selective inhibitor also designed for post-FGFR progression, has an FDA new drug application under Priority Review with a PDUFA target date of Sept. 27, 2026.
Tinengotinib has received Orphan Drug and Fast Track designations from the US FDA for cholangiocarcinoma and Orphan Drug designation from the European Medicines Agency for biliary tract cancer. TransThera said it will continue exploring the drug in prostate, breast, and liver cancer. A Phase III confirmatory study versus chemotherapy is ongoing in China.
The approval converts TransThera into a commercial-stage oncology company and gives it a first-mover position in China's post-FGFR cholangiocarcinoma market, a population with no prior approved options. Investors will watch the Phase III confirmatory readout and the drug's US regulatory path, where the FDA's September decision on Relay's rival lirafugratinib will set the competitive benchmark.
This article is for informational purposes only and does not constitute investment advice.
